Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe.

Bery N, Legg S, Debreczeni J, Breed J, Embrey K, Stubbs C, Kolasinska-Zwierz P, Barrett N, Marwood R, Watson J, Tart J, Overman R, Miller A, Phillips C, Minter R, Rabbitts TH.

Nat Commun. 2019 Jun 13;10(1):2607. doi: 10.1038/s41467-019-10419-2.

2.

Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3.

Chambers JS, Brend T, Rabbitts TH.

Sci Rep. 2019 Jun 12;9(1):8553. doi: 10.1038/s41598-019-44908-7.

3.

Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model.

Pais H, Ruggero K, Zhang J, Al-Assar O, Bery N, Bhuller R, Weston V, Kearns PR, Mecucci C, Miller A, Rabbitts TH.

Sci Rep. 2019 Apr 8;9(1):5760. doi: 10.1038/s41598-019-42214-w.

4.

Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves.

Zhang J, Shrivastava S, Cleveland RO, Rabbitts TH.

ACS Appl Mater Interfaces. 2019 Mar 20;11(11):10481-10491. doi: 10.1021/acsami.8b21398. Epub 2019 Mar 6.

5.

Bioluminescence Resonance Energy Transfer 2 (BRET2)-Based RAS Biosensors to Characterize RAS Inhibitors.

Bery N, Rabbitts TH.

Curr Protoc Cell Biol. 2019 Jun;83(1):e83. doi: 10.1002/cpcb.83. Epub 2019 Feb 15.

PMID:
30768855
6.

Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.

Cruz-Migoni A, Canning P, Quevedo CE, Bataille CJR, Bery N, Miller A, Russell AJ, Phillips SEV, Carr SB, Rabbitts TH.

Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2545-2550. doi: 10.1073/pnas.1811360116. Epub 2019 Jan 25.

7.

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.

Quevedo CE, Cruz-Migoni A, Bery N, Miller A, Tanaka T, Petch D, Bataille CJR, Lee LYW, Fallon PS, Tulmin H, Ehebauer MT, Fernandez-Fuentes N, Russell AJ, Carr SB, Phillips SEV, Rabbitts TH.

Nat Commun. 2018 Aug 9;9(1):3169. doi: 10.1038/s41467-018-05707-2.

8.

Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.

Bery N, Cruz-Migoni A, Bataille CJ, Quevedo CE, Tulmin H, Miller A, Russell A, Phillips SE, Carr SB, Rabbitts TH.

Elife. 2018 Aug 2;7. pii: e40515. doi: 10.7554/eLife.40515.

9.

BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.

Bery N, Cruz-Migoni A, Bataille CJ, Quevedo CE, Tulmin H, Miller A, Russell A, Phillips SE, Carr SB, Rabbitts TH.

Elife. 2018 Jul 10;7. pii: e37122. doi: 10.7554/eLife.37122. Erratum in: Elife. 2018 Aug 02;7:.

10.

Cloning, purification and structure determination of the HIV integrase-binding domain of lens epithelium-derived growth factor.

Hannon C, Cruz-Migoni A, Platonova O, Owen RL, Nettleship JE, Miller A, Carr SB, Harris G, Rabbitts TH, Phillips SEV.

Acta Crystallogr F Struct Biol Commun. 2018 Mar 1;74(Pt 3):143-149. doi: 10.1107/S2053230X18001553. Epub 2018 Feb 26.

11.

Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein.

Bao L, Hannon C, Cruz-Mignoni A, Ptchelkine D, Sun MY, Miller A, Bunjobpol W, Quevedo CE, Derveni M, Chambers J, Simmons A, Phillips SEV, Rabbitts TH.

Sci Rep. 2017 Dec 4;7(1):16869. doi: 10.1038/s41598-017-16742-2.

12.

A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS.

Bao L, Al-Assar O, Drynan LF, Arends MJ, Tyers P, Barker RA, Rabbitts TH.

Sci Rep. 2017 Mar 21;7:44899. doi: 10.1038/srep44899.

13.

LMO2 and IL2RG synergize in thymocytes to mimic the evolution of SCID-X1 gene therapy-associated T-cell leukaemia.

Ruggero K, Al-Assar O, Chambers JS, Codrington R, Brend T, Rabbitts TH.

Leukemia. 2016 Sep;30(9):1959-62. doi: 10.1038/leu.2016.116. Epub 2016 May 12. No abstract available.

14.

Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.

Town J, Pais H, Harrison S, Stead LF, Bataille C, Bunjobpol W, Zhang J, Rabbitts TH.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3603-8. doi: 10.1073/pnas.1521251113. Epub 2016 Mar 15.

15.

Selection of human single domain antibodies recognizing the CMYC protein using enhanced intracellular antibody capture.

Zeng J, Li HC, Tanaka T, Rabbitts TH.

J Immunol Methods. 2015 Nov;426:140-3. doi: 10.1016/j.jim.2015.08.009. Epub 2015 Aug 25.

PMID:
26319394
16.

LMO2 at 25 years: a paradigm of chromosomal translocation proteins.

Chambers J, Rabbitts TH.

Open Biol. 2015 Jun;5(6):150062. doi: 10.1098/rsob.150062. Review.

17.

Functional inhibition of β-catenin-mediated Wnt signaling by intracellular VHH antibodies.

Newnham LE, Wright MJ, Holdsworth G, Kostarelos K, Robinson MK, Rabbitts TH, Lawson AD.

MAbs. 2015;7(1):180-91. doi: 10.4161/19420862.2015.989023.

18.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

19.

Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions.

Zhang J, Rabbitts TH.

Biochim Biophys Acta. 2014 Nov;1844(11):1970-1976. doi: 10.1016/j.bbapap.2014.05.009. Epub 2014 May 29. Review.

PMID:
24881582
20.

Sequential gene targeting to make chimeric tumor models with de novo chromosomal abnormalities.

Chambers JS, Tanaka T, Brend T, Ali H, Geisler NJ, Khazin L, Cigudosa JC, Dear TN, MacLennan K, Rabbitts TH.

Cancer Res. 2014 Mar 1;74(5):1588-97. doi: 10.1158/0008-5472.CAN-13-1783. Epub 2014 Jan 13.

21.

Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.

Sewell H, Tanaka T, El Omari K, Mancini EJ, Cruz A, Fernandez-Fuentes N, Chambers J, Rabbitts TH.

Sci Rep. 2014 Jan 10;4:3643. doi: 10.1038/srep03643.

22.

Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes.

El-Jawhari JJ, El-Sherbiny YM, Scott GB, Morgan RS, Prestwich R, Bowles PA, Blair GE, Tanaka T, Rabbitts TH, Meade JL, Cook GP.

Mol Immunol. 2014 Apr;58(2):160-8. doi: 10.1016/j.molimm.2013.11.020. Epub 2013 Dec 22.

23.

Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.

McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, Tremblay CS, Rabbitts TH, Curtis DJ.

Blood. 2013 Sep 19;122(12):2093-103. doi: 10.1182/blood-2012-09-458570. Epub 2013 Aug 7.

24.

Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells.

Li BE, Gan T, Meyerson M, Rabbitts TH, Ernst P.

Blood. 2013 Sep 19;122(12):2039-46. doi: 10.1182/blood-2013-03-486647. Epub 2013 Aug 1.

25.
26.

Intracellular antibody capture (IAC) methods for single domain antibodies.

Tanaka T, Rabbitts TH.

Methods Mol Biol. 2012;911:151-73. doi: 10.1007/978-1-61779-968-6_10.

PMID:
22886251
27.

Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.

Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS.

Pharm Res. 2012 Apr;29(4):1098-109. doi: 10.1007/s11095-011-0654-8. Epub 2011 Dec 20.

28.

Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.

Tanaka T, Sewell H, Waters S, Phillips SE, Rabbitts TH.

J Biol Chem. 2011 Feb 4;286(5):3707-16. doi: 10.1074/jbc.M110.188193. Epub 2010 Oct 27.

29.

Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.

Tanaka T, Rabbitts TH.

Oncogene. 2010 Nov 11;29(45):6064-70. doi: 10.1038/onc.2010.346. Epub 2010 Sep 6.

PMID:
20818422
30.

Intracellular antibodies and cancer: new technologies offer therapeutic opportunities.

Pérez-Martínez D, Tanaka T, Rabbitts TH.

Bioessays. 2010 Jul;32(7):589-98. doi: 10.1002/bies.201000009.

PMID:
20544739
31.

Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer.

McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, Rabbitts TH, George PJ, Dear PH, Rabbitts PH.

Am J Respir Crit Care Med. 2010 Jul 1;182(1):83-91. doi: 10.1164/rccm.201001-0005OC. Epub 2010 Mar 18.

32.

The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.

McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ.

Science. 2010 Feb 12;327(5967):879-83. doi: 10.1126/science.1182378. Epub 2010 Jan 21.

33.

Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture.

Tanaka T, Rabbitts TH.

Nat Protoc. 2010 Jan;5(1):67-92. doi: 10.1038/nprot.2009.199. Epub 2009 Dec 17.

PMID:
20057382
34.

PCRPi: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces.

Assi SA, Tanaka T, Rabbitts TH, Fernandez-Fuentes N.

Nucleic Acids Res. 2010 Apr;38(6):e86. doi: 10.1093/nar/gkp1158. Epub 2009 Dec 11.

35.

Commonality but diversity in cancer gene fusions.

Rabbitts TH.

Cell. 2009 May 1;137(3):391-5. doi: 10.1016/j.cell.2009.04.034. Review.

36.

Selection of complementary single-variable domains for building monoclonal antibodies to native proteins.

Tanaka T, Rabbitts TH.

Nucleic Acids Res. 2009 Apr;37(5):e41. doi: 10.1093/nar/gkp069. Epub 2009 Feb 10.

37.

Microdissection molecular copy-number counting (microMCC)--unlocking cancer archives with digital PCR.

McCaughan F, Darai-Ramqvist E, Bankier AT, Konfortov BA, Foster N, George PJ, Rabbitts TH, Kost-Alimova M, Rabbitts PH, Dear PH.

J Pathol. 2008 Nov;216(3):307-16. doi: 10.1002/path.2413.

PMID:
18773450
38.

Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias.

Lobato MN, Metzler M, Drynan L, Forster A, Pannell R, Rabbitts TH.

J Natl Cancer Inst Monogr. 2008;(39):58-63. doi: 10.1093/jncimonographs/lgn022.

PMID:
18648005
39.

Interfering with protein-protein interactions: potential for cancer therapy.

Tanaka T, Rabbitts TH.

Cell Cycle. 2008 Jun 1;7(11):1569-74. Epub 2008 Apr 2. Review.

PMID:
18469527
40.

An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.

Nam CH, Lobato MN, Appert A, Drynan LF, Tanaka T, Rabbitts TH.

Oncogene. 2008 Aug 21;27(36):4962-8. doi: 10.1038/onc.2008.130. Epub 2008 Apr 28.

PMID:
18438427
41.

Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias.

Cano F, Pannel R, Follows GA, Rabbitts TH.

Mol Cancer Ther. 2008 Mar;7(3):730-5. doi: 10.1158/1535-7163.MCT-07-2032.

42.

MLL gene fusions in human leukaemias: in vivo modelling to recapitulate these primary tumourigenic events.

Rodriguez-Perales S, Cano F, Lobato MN, Rabbitts TH.

Int J Hematol. 2008 Jan;87(1):3-9. doi: 10.1007/s12185-007-0001-3. Epub 2007 Nov 17.

PMID:
18224407
43.

Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds.

Tanaka T, Rabbitts TH.

J Mol Biol. 2008 Feb 22;376(3):749-57. doi: 10.1016/j.jmb.2007.11.085. Epub 2007 Dec 4.

PMID:
18187153
44.

The role of Slit-Robo signaling in the generation, migration and morphological differentiation of cortical interneurons.

Andrews W, Barber M, Hernadez-Miranda LR, Xian J, Rakic S, Sundaresan V, Rabbitts TH, Pannell R, Rabbitts P, Thompson H, Erskine L, Murakami F, Parnavelas JG.

Dev Biol. 2008 Jan 15;313(2):648-58. Epub 2007 Nov 13.

45.

Leukaemia lineage specification caused by cell-specific Mll-Enl translocations.

Cano F, Drynan LF, Pannell R, Rabbitts TH.

Oncogene. 2008 Mar 20;27(13):1945-50. Epub 2007 Oct 1.

PMID:
17906700
46.

Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.

Tanaka T, Williams RL, Rabbitts TH.

EMBO J. 2007 Jul 11;26(13):3250-9. Epub 2007 Jun 14.

47.

Interrogation of genomes by molecular copy-number counting (MCC).

Daser A, Thangavelu M, Pannell R, Forster A, Sparrow L, Chung G, Dear PH, Rabbitts TH.

Nat Methods. 2006 Jun;3(6):447-53. Erratum in: Nat Methods. 2006 Jul;3(7):579.

PMID:
16721378
48.

A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology.

Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, Rabbitts TH.

Oncogene. 2006 May 25;25(22):3093-103.

PMID:
16607274
49.
50.

Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.

Drynan LF, Pannell R, Forster A, Chan NM, Cano F, Daser A, Rabbitts TH.

EMBO J. 2005 Sep 7;24(17):3136-46. Epub 2005 Aug 11.

Supplemental Content

Loading ...
Support Center